» Articles » PMID: 34794461

Extranodal Natural Killer/T-cell Lymphoma of the Breast: a Retrospective Clinicopathological Analysis of a Consecutive 11-year Case Series

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2021 Nov 19
PMID 34794461
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Extranodal NK/T-cell lymphoma of the breast (ENKTL-Breast) is rarely detected in clinical practice, and its clinicopathological features remain unclear.

Results: A consecutive 11-year (2010-2020) ENKTL-Breast case series was retrospectively analyzed. Eight cases of ENKTL-Breast were selected, with three primary and five secondary lesions, accounting for 3.5% (8/228) of all breast lymphomas. All patients were female with a median age of 46 years. Lesions presented as solid breast masses (8/8, 100%) and were usually located in the upper outer quadrant of the breast (7/8, 87.5%). B-symptoms were observed in seven (7/8, 87.5%) cases. Two primary ENKTL-Breast cases showed concomitant diseases (IgA nephropathy and chronic active hepatitis B). Histological and immunohistochemical features of ENKTL-Breast were similar to those of ENKTL at other sites. T-cell receptor rearrangement revealed clonality in all examined primary cases (2/2, 100%), but only in one secondary case (1/5, 20%). The disease progressed rapidly in two primary cases and both patients died within 3 and 9 months. For secondary cases, the disease manifested as a disseminated disease, with a median survival time of 6 months.

Conclusions: Our data suggested that ENKTL-Breast clinically mimics breast cancer to some extent, though B-symptoms might serve as a distinguishing factor. ENKTL-Breast is highly aggressive and patients with this disease exhibit a short survival time. Primary ENKTL-Breast tends to originate from activated cytotoxic T-cells, and immune-related diseases may be involved in its pathogenesis and development.

Citing Articles

Extranodal natural killer/T-cell lymphoma with hepatosplenic involvement: a retrospective study of a consecutive 14-year case series.

Zhang Y, Li Z, Zhao S, Zhang W, Liu Q, Liu W Ann Hematol. 2023; 102(10):2803-2813.

PMID: 37434096 DOI: 10.1007/s00277-023-05358-4.

References
1.
Cheah C, Campbell B, Seymour J . Primary breast lymphoma. Cancer Treat Rev. 2014; 40(8):900-8. DOI: 10.1016/j.ctrv.2014.05.010. View

2.
Zhou Z, Xie J, Wei P, Zhou X . [Pathologic subtyping of primary lymphoma of breast and prognostic analysis]. Zhonghua Bing Li Xue Za Zhi. 2017; 46(9):618-622. DOI: 10.3760/cma.j.issn.0529-5807.2017.09.006. View

3.
Chan J, Yip T, Tsang W, Ng C, Lau W, Poon Y . Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol. 1994; 18(9):938-46. DOI: 10.1097/00000478-199409000-00009. View

4.
Talwalkar S, Miranda R, Valbuena J, Routbort M, Martin A, Medeiros L . Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol. 2008; 32(9):1299-309. DOI: 10.1097/PAS.0b013e318165eb50. View

5.
Avenia N, Sanguinetti A, Cirocchi R, Bistoni G, Trastulli S, DAjello F . Primary breast lymphomas: a multicentric experience. World J Surg Oncol. 2010; 8:53. PMC: 2903594. DOI: 10.1186/1477-7819-8-53. View